-
Acta Poloniae Pharmaceutica 2001
Topics: Cyclodextrins; Hydrogen-Ion Concentration; Methotrimeprazine; Solubility; Temperature; Thermodynamics
PubMed: 11501787
DOI: No ID Found -
Agressologie: Revue Internationale de... 1968
Topics: Animals; Dogs; Haplorhini; Methotrimeprazine; Mice; Rats
PubMed: 4970890
DOI: No ID Found -
Supportive Care in Cancer : Official... Sep 2005Nausea and vomiting are distressing symptoms affecting between 20% and 70% of patients with advanced cancer. Methotrimeprazine is a phenothiazine antipsychotic used in... (Comparative Study)
Comparative Study
INTRODUCTION
Nausea and vomiting are distressing symptoms affecting between 20% and 70% of patients with advanced cancer. Methotrimeprazine is a phenothiazine antipsychotic used in palliative care for the management of terminal agitation and nausea/vomiting but there is only anecdotal evidence to support its use in palliative care.
AIM
To establish whether nausea/vomiting in palliative care patients is improved by the administration of low-dose methotrimeprazine.
METHODS
Patients with advanced malignancy were entered at different treatment levels according to symptom severity. The dose was altered according to response (minimum dose 6.25 mg daily po, maximum 25 mg by 24-h subcutaneous infusion). Symptoms and side effects were recorded daily from 0 (baseline) to day 5 using a four-point scale. Any improvement in nausea/vomiting score was taken as a response.
RESULTS
Sixty-five patients were entered. The cause of nausea and vomiting was multifactorial in the majority of patients, 35/65 (54%). As expected in a study of patients with poor performance status, the attrition rate was high. Of 53 patients evaluable for response at day 2, 33 (62%) showed some improvement in nausea or vomiting. At day 5, improvement was seen in 20/34 (58%). There was no significant change in "side effects" from baseline with time.
CONCLUSION
These results suggest that methotrimeprazine has antiemetic activity.
Topics: Adult; Aged; Aged, 80 and over; Dopamine Antagonists; Dose-Response Relationship, Drug; Female; Humans; Male; Methotrimeprazine; Middle Aged; Nausea; Neoplasms; Treatment Outcome; Vomiting; Withholding Treatment
PubMed: 15700129
DOI: 10.1007/s00520-004-0768-1 -
Therapeutic Drug Monitoring Nov 1990A new analytical method has been developed for simultaneous quantitation of levomepromazine and its five main metabolites in serum and urine. The method uses C-2 bonded...
A new analytical method has been developed for simultaneous quantitation of levomepromazine and its five main metabolites in serum and urine. The method uses C-2 bonded phase extraction and reversed-phase high-performance liquid chromatography, based on ion-pair formation with dodecyl sulfate. The detection limits were 15 nM for levomepromazine and N-desmethyl levomepromazine, 28 nM for levomepromazine sulfoxide, and 56 nM for 3-hydroxylevomepromazine. 7-hydroxylevomepromazine, and O-desmethyllevomepromazine in serum, and lower in urine. The method was applied to measure steady-state serum and urine concentrations of levomepromazine and metabolites in five psychiatric patients. The concentrations of levomepromazine sulfoxide and N-desmethyllevomepromazine were generally higher than the concentrations of levomepromazine. The hydroxylated and O-demethylated metabolites were also found in higher concentrations than levomepromazine, but mainly as conjugates.
Topics: Blood Specimen Collection; Chromatography, High Pressure Liquid; Humans; Methotrimeprazine
PubMed: 2275005
DOI: 10.1097/00007691-199011000-00011 -
Journal of Pain and Symptom Management Mar 1989
Topics: Acetaminophen; Adenocarcinoma; Female; Humans; Intestinal Obstruction; Lung Neoplasms; Methotrimeprazine; Middle Aged; Narcotics; Pain
PubMed: 2703737
DOI: 10.1016/0885-3924(89)90065-1 -
The Veterinary Record Apr 1986
Topics: Anesthesia; Animals; Drug Combinations; Etorphine; Methotrimeprazine; Morphinans
PubMed: 3716097
DOI: 10.1136/vr.118.14.406-b -
Journal of Pharmaceutical Sciences Feb 1977Two metabolites of methotrimeprazine, the sulfoxide and the demethylated analog, were identified in extracts from patient plasma by combined GLC-mass spectrometry....
Two metabolites of methotrimeprazine, the sulfoxide and the demethylated analog, were identified in extracts from patient plasma by combined GLC-mass spectrometry. Methotrimeprazine and its sulfoxide had similar mass spectra but different GLC retention times. In addition to the metabolites found in plasma, two other metabolites, the didesmethyl analog and the monodesmethyl sulfoxide, were identified in a urine extract.
Topics: Adult; Chromatography, Gas; Female; Humans; Male; Mass Spectrometry; Methotrimeprazine; Middle Aged; Time Factors
PubMed: 839414
DOI: 10.1002/jps.2600660214 -
The Veterinary Record Apr 1986
Topics: Animals; Cats; Drug Combinations; Etorphine; Hand Injuries; Humans; Methotrimeprazine; Morphinans
PubMed: 3716112
DOI: 10.1136/vr.118.16.466-a -
Southwestern Medicine May 1967
Clinical Trial
Topics: Adolescent; Adult; Aged; Analgesics; Child; Child, Preschool; Clinical Trials as Topic; Female; Humans; Injections, Intramuscular; Male; Methotrimeprazine; Middle Aged; Postoperative Complications
PubMed: 4859792
DOI: No ID Found -
Soins. Psychiatrie Mar 1985
Topics: Humans; Methotrimeprazine
PubMed: 3847157
DOI: No ID Found